Researchers present a new potential "weapon" for the destruction of tumour cells. Its name is MEN1309 and this new antibody is currently being studied by researchers at Menarini and Oxford Bio Therapeutics (OBT) against Non Hodgkin's lymphomas and solid tumours.

2014 - An independent Corporate Reputation Survey of Pharma Companies, including 800 patient groups in 43 countries worldwide, ranked Menarini amongst the world's top ten Pharmaceutical companies closest to patients' needs. Menarini Climbs Up the Ranking to be Amongst Top Ten Companies Considered the Most "Patient Friendly"

A recent 2013 Asia-Pacific Sexual Behaviours and Satisfaction Survey[ii] revealed that 61% of men and 39% of women in Singapore believe that the man's ability to control when to ejaculate is critical to achieving mutual sexual satisfaction, and the desired intimacy of successful relationships.

Singapore - 14 February 2014 – Moberg Pharma AB (OMX: MOB) and Menarini Asia-Pacific, a member of the Menarini Group are pleased to announce that Menarini Asia-Pacific has been granted the exclusive rights to market and sell Kerasal Nail™ in eight Southeast Asian countries.